MedTrace Logo

Population Pharmacokinetics of Cephalosporins and Macrolides in Chinese Children With Community Acquired Pneumonia

NCT02775968 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 750

Last updated 2017-06-26

No results posted yet for this study

Summary

This study is based on the hypothesis that the pharmacokinetics of antibiotics in children is different from adults. Cephalosporins and macrolide antibiotics are the common drugs for children with community acquired pneumonia, the investigators aim to study the population pharmacokinetics of cephalosporins and macrolide antibiotics in children receiving the drug for treatment of community acquired pneumonia, and to correlate it with treatment effectiveness and incidence of adverse effects.

Potential Impact: This novel knowledge will allow better and more rational approaches to the treatment of community acquired pneumonia. It will also set the foundation for further studies that will be able to test improved therapies that may increase treatment response in vulnerable children.

Conditions

  • Community Acquired Pneumonia

Interventions

DRUG

Cephalosporins and Macrolide Antibiotics

The intervention drugs are prescribed by treating caregiver.

Sponsors & Collaborators

  • Beijing Children's Hospital

    lead OTHER

Principal Investigators

  • A-Dong Shen, Master · Beijing Children's Hospital of Capital Medical University, China

  • Bao-Ping Xu, MD · Beijing Children's Hospital of Capital Medical University, China; China National Clinical Research Center for Respiratory Diseases

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-21
Primary Completion
2022-08-31
Completion
2022-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02775968 on ClinicalTrials.gov